Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology.


Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
01 2021
Historique:
received: 20 04 2020
accepted: 11 09 2020
entrez: 19 1 2021
pubmed: 20 1 2021
medline: 13 10 2021
Statut: epublish

Résumé

Because obesity affects the cellular immune response to infections, we aimed to investigate whether high body mass index (BMI) in young adulthood and high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels interact with regard to MS risk. We also aimed at exploring potential 3-way interactions between BMI at age 20 years, aspects of Epstein-Barr virus (EBV) infection (high EBNA-1 antibody levels and infectious mononucleosis [IM] history, respectively) and the human leukocyte antigen Using Swedish population-based case-control studies (5,460 cases and 7,275 controls), we assessed MS risk in relation to interactions between overweight/obesity at age 20 years, IM history, EBNA-1 levels, and Overweight/obesity, compared with normal weight, interacted significantly with high (>50th percentile) EBNA-1 antibody levels (attributable proportion due to interaction 0.2, 95% CI 0.1-0.4). The strength of the interaction increased with higher category of EBNA-1 antibody levels. Furthermore, 3-way interactions were present between With regard to MS risk, overweight/obesity in young adulthood acts synergistically with both aspects of EBV infection, predominantly among those with a genetic susceptibility to the disease. The obese state both induces a chronic immune-mediated inflammation and affects the cellular immune response to infections, which may contribute to explain our findings.

Identifiants

pubmed: 33465039
pii: 8/1/e912
doi: 10.1212/NXI.0000000000000912
pmc: PMC7803338
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Epstein-Barr Virus Nuclear Antigens 0
HLA-DRB1 Chains 0
HLA-DRB1*15:01 antigen 0
EBV-encoded nuclear antigen 1 O5GA75RST7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Eur J Neurol. 2012 Jul;19(7):955-62
pubmed: 22289117
Neurology. 2009 Nov 10;73(19):1543-50
pubmed: 19901245
Genes Immun. 2012 Jan;13(1):14-20
pubmed: 21776012
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Nat Genet. 2015 Oct;47(10):1107-1113
pubmed: 26343388
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16955-16960
pubmed: 31375628
Nestle Nutr Workshop Ser Pediatr Program. 2009;63:151-9; discussion 159-62, 259-68
pubmed: 19346774
Neurology. 2014 Mar 11;82(10):865-72
pubmed: 24500647
Mult Scler. 2019 Feb;25(2):180-186
pubmed: 30251921
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Neurology. 2018 Apr 3;90(14):e1191-e1199
pubmed: 29514944
Clin Chem. 2005 Oct;51(10):1845-53
pubmed: 16099939
Expert Rev Clin Immunol. 2011 May;7(3):287-94
pubmed: 21595595
Front Neurol. 2020 Jan 24;10:1368
pubmed: 32038456
Int J Obes Relat Metab Disord. 1995 Aug;19(8):570-2
pubmed: 7489028
J Leukoc Biol. 2008 Oct;84(4):893-9
pubmed: 18552206
Acta Neurol Scand. 2015;132(199):11-9
pubmed: 26046553
Exp Biol Med (Maywood). 2010 Dec;235(12):1412-24
pubmed: 21127339
Arch Neurol. 2006 Jun;63(6):839-44
pubmed: 16606758
Diabetes. 2007 Jan;56(1):16-23
pubmed: 17192460
PLoS One. 2010 Sep 01;5(9):
pubmed: 20824132
Eur J Neurol. 2015 Mar;22(3):578-e38
pubmed: 25530445
Autoimmun Rev. 2014 Sep;13(9):981-1000
pubmed: 25092612
Mult Scler. 2012 Sep;18(9):1334-6
pubmed: 22328681
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Science. 2019 Sep 27;365(6460):
pubmed: 31604244
Arthritis Rheum. 2004 Oct;50(10):3085-92
pubmed: 15476204
PLoS Comput Biol. 2013;9(2):e1002877
pubmed: 23459081
Med Chem. 2018 Feb 6;14(2):129-143
pubmed: 28933265
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Epidemiology. 2009 Jan;20(1):6-13
pubmed: 19234396

Auteurs

Anna Karin Hedström (AK)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden. anna.hedstrom@ki.se.

Nicole Brenner (N)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Julia Butt (J)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Jan Hillert (J)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Tim Waterboer (T)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Tomas Olsson (T)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Lars Alfredsson (L)

From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH